as the causative drug for gingival overgrowth.
However, there is no report of nisoldipine-induced gingival overgrowth. Thus, we determined whether nisoldipine is the causative drug for gingival overgrowth. Furthermore, since the incidence of gingival overgrowth induced by calcium channel blocker remains poorly defined, the incidences of 13 calcium channel blockers were also determined. Results: The first case of gingival overgrowth induced by nisoldipine was found in one patient (Fig) , which was clinically and histologically similar to those of other calcium channel blockers. Since marked reduction of gingival overgrowth was evident two months after withdrawal of nisoldipine, we concluded that this case was a nisoldipineinduced gingival overgrowth. In other drugs, the gingival overgrowth was also found in patients receiving amlodipine (n = 1), diltiazem (n = 7), manidipine (n = 1), nicardipine (n = 1) and nifedipine (n = 22) ( Table), 
